Effect of Community-Based Occupational Therapy on Health-Related Quality of Life and Engagement in Meaningful Activities of Women with Breast Cancer
Table 3
Distribution of evaluation scores in health-related quality of life questionnaire scales in the groups at baseline.
Scales of the quality of life questionnaires
Experimental group
U; p ⟷
Control group
(11)
–
(11)
–
EORTC QLQ C-30
Global health status/QoL
11
50 (33.33–83.33; 50.75)
41.5; 0.217
11
58.33 (33.33–91.67; 59.85)
Functional scales
Physical functioning
11
60 (40–86.67; 63.64)
50; 0.519
11
73.33 (46.67–86.67; 67.88)
Role functioning
11
66.67 (16.67–100; 68.18)
60; 1
11
66.67 (33.33–100; 69.7)
Emotional functioning
11
50 (8.33–100; 52.27)
36.5; 0.116
11
66.67 (8.33–100; 65.91)
Cognitive functioning
11
50 (0–83.33; 54.55)
35.5; 0.101
11
83.33 (50–100; 72.73)
Social functioning
11
50 (16.67–83.33; 48.49)
32; 0.065
11
66.67 (50–100; 69.7)
Symptom scales
Fatigue
11
55.56 (33.33–77.78; 54.55)
54.5; 0.699
11
44.44 (11.11–88.89; 50.5)
Nausea and vomiting
11
0 (0–50; 7.58)
54.5; 0.699
11
0 (0–66.67; 12.12)
Pain
11
33.33 (0–83.33; 34.85)
56; 0.797
11
33.33 (0–83.33; 28.79)
Dyspnoea
11
0 (0–33.33; 15.15)
50; 0.519
11
33.33 (0–66.67; 24.24)
Insomnia
11
66.67 (0–100; 66.67)
39; 0.171
11
66.67 (0–66.67; 48.49)
Appetite loss
11
0 (0–33.33; 9.09)
44; 0.3
11
33.33 (0–33.33; 18.18)
Constipation
11
33.33 (0–100; 42.42)
48; 0.438
11
0 (0–100; 24.24)
Diarrhoea
11
0 (0–66.67; 9.09)
60; 1
11
0 (0–100; 12.12)
Financial difficulties
11
66.67 (33.33–100; 69.7)
42; 0.243
11
66.67 (0–100; 51.52)
EORTC QLQ BR-23
Functional scales
Body image
11
58.33 (0–83.33; 51.51)
28.5; 0.562
11
41.57 (25–91.67; 48.48)
Sexual functioning
11
100 (0–100; 81.82)
60; 1
11
100 (33.33–100; 81.82)
Sexual enjoyment
5
66.67 (33.33–100; 73.33)
9; 0.548
5
66.67 (33.33–100; 60)
Future perspective
11
33.33 (0–66.67; 33.33)
51.5; 0.562
11
33.33 (0–66.67; 27.27)
Symptom scales
Systemic therapy side effects
11
23.81 (4.76–61.90; 31.6)
58; 0.898
11
28.57 (4.76–57.14; 29)
Breast symptoms
11
41.67 (8.33–75; 38.64)
41; 0.217
11
25 (0–66.67; 28.79)
Arm symptoms
11
33.33 (0–77.78; 37.37)
63; 0.898
11
44.44 (0–88.89; 38.38)
Upset by hair loss
6
16.67 (0–33.33; 16.67)
28.5; 0.573
8
33.33 (0–100; 29.17)
Statistical significance was determined according to the nonparametric Mann–Whitney-Wilcoxon criterion, no significant differences between the groups, ≥ 0.05.
